Skip to main content
CivicGate

S 3598
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

Better Care for PFAS Patients Act of 2026

To provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), and for other purposes.

Introduced Jan 8, 2026

Latest action (Jan 8, 2026) Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Policy area
Issues
Healthcare

Summary

  • Requires the Director of the Agency for Toxic Substances and Disease Registry to contract with the National Academies of Sciences, Engineering, and Medicine to assess the health effects of PFAS and formulate clinical recommendations.
  • Requires the initial assessment and recommendations to be completed within two years, with updates at least every five years or more frequently as determined necessary based on scientific developments.
  • Requires the entity conducting the assessment to engage with PFAS-exposed communities and solicit their input regarding their experiences with PFAS exposure, testing, and clinical follow-up.
  • Requires the Director to issue up-to-date clinical guidance on addressing PFAS health effects within five years of the agreement and post it on the Agency website.
  • Requires the Director to disseminate the PFAS clinical guidance to State and local public health authorities and health care professionals, and update it at least every five years or more frequently as determined necessary.

AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.

Sponsor (1)

1 cosponsor

Money behind the sponsor

Top reported contributors to Jeanne Shaheen’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.

  • THEGROUP $16,200
  • BLINK TECH INC. $13,200
  • PARKER MEGGITT $7,725
  • INSIGHT $7,600
  • FAROS PROPERTIES $6,600

Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Jeanne Shaheen → · Outside spending →

Actions (2)

  1. Jan 8, 2026 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. · senate
  2. Jan 8, 2026 Introduced in Senate

Full text

IN THE SENATE OF THE UNITED STATES

January 8 (legislative day, January 7), 2026

Mrs. Shaheen (for herself and Ms. Collins) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Better Care for PFAS Patients Act of 2026”.

SEC. 2. PFAS HEALTH EFFECTS ASSESSMENT, RECOMMENDATIONS, AND GUIDANCE.

(a) Periodic Assessment and Recommendations.—

(1) Agreement.—The Director of the Agency for Toxic Substances and Disease Registry (in this section referred to as the “Director”) shall enter into an agreement with the National Academies of Sciences, Engineering, and Medicine (or another appropriate entity if the National Academies declines to enter into such agreement) under which the National Academies or the other appropriate entity agrees—

(A) to assess the health effects of per- and polyfluoroalkyl substances (in this section referred to as “PFAS”) that can be measured in human tissues;

(B) to formulate clinical recommendations on addressing such health effects;

(C) not later than 2 years after the date of entry into such agreement, to complete the initial assessment under subparagraph (A) and formulate the initial recommendations under subparagraph (B); and

(D) to update the most recent assessment and recommendations under this paragraph—

(i) every 5 years; or

(ii) more frequently as determined necessary by the Director based on an assessment of the science.

(2) Consultation.—In carrying out the assessments under paragraph (1), the National Academies of Sciences, Engineering, and Medicine or other appropriate entity shall engage with PFAS exposed communities and solicit input from members of such communities regarding their experiences with PFAS exposure, testing, and clinical follow-up.

(3) Timing of entry into agreement.—The Director shall enter into the agreement required by paragraph (1) not later than 60 days after the date of enactment of this Act.

(b) Up-to-Date Guidance.—Based on the results of the most recent assessment and recommendations under subsection (a), the Director, in consultation with the entity with which the Director enters into the agreement under subsection (a), shall—

(1) not later than 5 years after the date of entry into the agreement required by subsection (a)—

(A) issue up-to-date clinical guidance on addressing the health effects of PFAS;

(B) post such guidance on the public website of the Agency for Toxic Substances and Disease Registry; and

(C) disseminate such guidance to State and local public health authorities and appropriate health care professionals; and

(2) every 5 years thereafter, or more frequently as determined necessary by the Director based on an assessment of the science, issue, post, and disseminate up-to-date guidance as described in paragraph (1). <all>

Similar bills (6)

Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.

Comments

Comments

Loading comments…